IMMIX BIOPHARMA INC. - COMMON STOCK

Immix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board

01 Sep 2023 08:39:00 By Nasdaq GlobeNewswire

U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma

23 Aug 2023 08:37:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board

18 Aug 2023 09:20:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces Additional NXC-201 AL Amyloidosis Clinical Data Accepted for Oral Presentation at the 20th International Myeloma Society Annual Meeting (September 27-30, Athens Greece)

16 Aug 2023 09:05:00 By Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting

25 Jul 2023 08:42:00 By Nasdaq GlobeNewswire

Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial

17 Jul 2023 09:37:00 By Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

10 Jul 2023 09:47:00 By Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial

26 Jun 2023 09:49:00 By Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors

22 Jun 2023 09:53:00 By Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors

20 Jun 2023 09:45:00 By Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson Independent Director, to Board of Directors

16 Jun 2023 09:43:00 By Nasdaq GlobeNewswire

Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program

14 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors

12 Jun 2023 09:49:00 By Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site

26 May 2023 09:53:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial

21 May 2023 16:00:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)

04 May 2023 12:30:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody Tislelizumab

03 May 2023 08:00:00 By Nasdaq GlobeNewswire

Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris

26 Apr 2023 17:30:00 By Nasdaq GlobeNewswire

Nexcella, an Immix Biopharma subsidiary, announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting

04 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells

31 Mar 2023 08:00:00 By Nasdaq GlobeNewswire